{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:19:35Z","timestamp":1794507575494,"version":"4.9.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Contralateral risk-reducing mastectomy (CRRM) rates have tripled over the last 2 decades. Reasons for this are multi-factorial, with those harbouring a pathogenic variant in the<jats:italic>BRCA1<\/jats:italic>\/<jats:italic>2<\/jats:italic>gene having the greatest survival benefit. On May 14th, 2013, Angelina Jolie shared the news of her bilateral risk-reducing mastectomy (BRRM), on the basis of her<jats:italic>BRCA1<\/jats:italic>pathogenic variant status. We evaluated the impact of this news on rates of CRRM in women with increased risk for developing breast cancer after being diagnosed with unilateral breast cancer. The prospective cohort study included all women with at least a moderate lifetime risk of developing breast cancer who attended our family history clinic (1987\u20132019) and were subsequently diagnosed with unilateral breast cancer. Rates of CRRM were then compared between patients diagnosed with breast cancer before and after Angelina Jolie\u2019s announcement (pre- vs. post-AJ). Of 386 breast cancer patients, with a mean age at diagnosis of 48\u2009\u00b1\u20098\u00a0years, 268 (69.4%) were diagnosed in the pre-AJ period, and 118 (30.6%) in the post-AJ period. Of these, 123 (31.9%) underwent CRRM, a median 42 (interquartile range: 11\u201354) days after the index cancer surgery. Rates of CRRM doubled following AJ\u2019s news, from 23.9% pre-AJ to 50.0% post AJ (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Rates of CRRM were found to decrease with increasing age at breast cancer (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and tumour TNM stage (<jats:italic>p<\/jats:italic>\u2009=\u20090.040), and to increase with the estimated lifetime risk of breast cancer (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and tumour grade (<jats:italic>p<\/jats:italic>\u2009=\u20090.015) on univariable analysis. After adjusting for these factors, the step-change increase in CRRM rates post-AJ remained significant (odds ratio: 9.61,<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The AJ effect appears to have been associated with higher rates of CRRM amongst breast cancer patients with increased cancer risk. CRRM rates were highest amongst younger women and those with the highest lifetime risk profile. Clinicians need to be aware of how media news can impact on the delivery of cancer related services. Communicating objective assessment of risk is important when counselling women on the merits of risk-reducing surgery.<\/jats:p>","DOI":"10.1038\/s41598-021-82654-x","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T12:57:54Z","timestamp":1612270674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Narendra Nath","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hodson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaunak","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashu","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Wisely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsey","family":"Highton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lester","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cliona C.","family":"Kirwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Baildam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Gareth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"issue":"33","key":"82654_CR1","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1200\/JCO.2007.12.3141","volume":"25","author":"TM Tuttle","year":"2007","unstructured":"Tuttle, T. M., Habermann, E. B., Grund, E. H., Morris, T. J. & Virnig, B. A. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J. Clin. Oncol. 25(33), 5203\u20135209 (2007).","journal-title":"J. Clin. Oncol."},{"key":"82654_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/SLA.0000000000001698","volume":"265","author":"SM Wong","year":"2016","unstructured":"Wong, S. M. et al. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann. Surg. 265, 581\u2013589 (2016).","journal-title":"Ann. Surg."},{"issue":"12","key":"82654_CR3","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.2010.32.7395","volume":"29","author":"HB Nichols","year":"2011","unstructured":"Nichols, H. B., Berrington de Gonzalez, A., Lacey, J. V. Jr., Rosenberg, P. S. & Anderson, W. F. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J. Clin. Oncol. 29(12), 1564\u20131569 (2011).","journal-title":"J. Clin. Oncol."},{"key":"82654_CR4","first-page":"901046","volume":"2015","author":"NN Basu","year":"2015","unstructured":"Basu, N. N., Barr, L., Ross, G. L. & Evans, D. G. Contralateral risk-reducing mastectomy: review of risk factors and risk-reducing strategies. Int. J. Surg. Oncol. 2015, 901046 (2015).","journal-title":"Int. J. Surg. Oncol."},{"key":"82654_CR5","first-page":"CD002748","volume":"4","author":"NE Carbine","year":"2018","unstructured":"Carbine, N. E., Lostumbo, L., Wallace, J. & Ko, H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database Syst. Rev. 4, CD002748 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"82654_CR6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-013-2583-1","volume":"140","author":"DG Evans","year":"2013","unstructured":"Evans, D. G. et al. Contralateral mastectomy improves survival in women with BRCA1\/2-associated breast cancer. Breast Cancer Res. Treat. 140(1), 135\u2013142 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"82654_CR7","doi-asserted-by":"publisher","first-page":"g226","DOI":"10.1136\/bmj.g226","volume":"348","author":"K Metcalfe","year":"2014","unstructured":"Metcalfe, K. et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 348, g226 (2014).","journal-title":"BMJ"},{"issue":"3","key":"82654_CR8","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ijc.29032","volume":"136","author":"BA Heemskerk-Gerritsen","year":"2015","unstructured":"Heemskerk-Gerritsen, B. A. et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int. J. Cancer 136(3), 668\u2013677 (2015).","journal-title":"Int. J. Cancer"},{"issue":"4","key":"82654_CR9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10689-015-9825-9","volume":"14","author":"NN Basu","year":"2015","unstructured":"Basu, N. N. et al. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Fam. Cancer 14(4), 531\u2013538 (2015).","journal-title":"Fam. Cancer"},{"issue":"6","key":"82654_CR10","doi-asserted-by":"publisher","first-page":"R156","DOI":"10.1186\/bcr3369","volume":"14","author":"K Rhiem","year":"2012","unstructured":"Rhiem, K. et al. The risk of contralateral breast cancer in patients from BRCA1\/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res. 14(6), R156 (2012).","journal-title":"Breast Cancer Res."},{"key":"82654_CR11","unstructured":"Jolie A. My medical choice. New York Times. Sect. Opinion (2013)."},{"key":"82654_CR12","doi-asserted-by":"publisher","first-page":"i6357","DOI":"10.1136\/bmj.i6357","volume":"355","author":"S Desai","year":"2016","unstructured":"Desai, S. & Jena, A. B. Do celebrity endorsements matter? Observational study of BRCA gene testing and mastectomy rates after Angelina Jolie\u2019s New York Times editorial. BMJ 355, i6357 (2016).","journal-title":"BMJ"},{"issue":"5","key":"82654_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s13058-014-0442-6","volume":"16","author":"DG Evans","year":"2014","unstructured":"Evans, D. G. et al. The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res. 16(5), 442 (2014).","journal-title":"Breast Cancer Res."},{"key":"82654_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13058-015-0650-8","volume":"17","author":"DG Evans","year":"2015","unstructured":"Evans, D. G. et al. Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women. Breast Cancer Res. 17, 143 (2015).","journal-title":"Breast Cancer Res."},{"issue":"2","key":"82654_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4048\/jbc.2017.20.2.203","volume":"20","author":"J Lee","year":"2017","unstructured":"Lee, J. et al. Influence of the Angelina Jolie announcement and insurance reimbursement on practice patterns for hereditary breast cancer. J. Breast Cancer 20(2), 203\u2013207 (2017).","journal-title":"J. Breast Cancer"},{"issue":"5","key":"82654_CR16","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/j.amepre.2017.05.016","volume":"53","author":"H Nabi","year":"2017","unstructured":"Nabi, H., Dorval, M., Chiquette, J. & Simard, J. Increased use of BRCA mutation test in unaffected women over the period 2004\u20132014 in the U.S.: further evidence of the \u201cAngelina Jolie Effect\u201d?. Am. J. Prev. Med. 53(5), e195\u2013e196 (2017).","journal-title":"Am. J. Prev. Med."},{"issue":"2","key":"82654_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10549-018-4824-9","volume":"171","author":"A Liede","year":"2018","unstructured":"Liede, A. et al. Risk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effect. Breast Cancer Res. Treat. 171(2), 435\u2013442 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"82654_CR18","unstructured":"Pitt, A. J. Diary of a Surgery. New York TImes. 2015 March (2015)."},{"issue":"10","key":"82654_CR19","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1001\/jama.279.10.762","volume":"279","author":"AB Nattinger","year":"1998","unstructured":"Nattinger, A. B., Hoffmann, R. G., Howell-Pelz, A. & Goodwin, J. S. Effect of Nancy Reagan\u2019s mastectomy on choice of surgery for breast cancer by US women. JAMA 279(10), 762\u2013766 (1998).","journal-title":"JAMA"},{"key":"82654_CR20","unstructured":"Kolata, G. Mastectomy Seen as Extreme Treatment New York Times (1987)."},{"issue":"10","key":"82654_CR21","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1245\/s10434-009-0641-z","volume":"16","author":"AK Arrington","year":"2009","unstructured":"Arrington, A. K., Jarosek, S. L., Virnig, B. A., Habermann, E. B. & Tuttle, T. M. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann. Surg. Oncol. 16(10), 2697\u20132704 (2009).","journal-title":"Ann. Surg. Oncol."},{"issue":"6","key":"82654_CR22","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1245\/s10434-009-0362-3","volume":"16","author":"ME Sorbero","year":"2009","unstructured":"Sorbero, M. E., Dick, A. W., Beckjord, E. B. & Ahrendt, G. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann. Surg. Oncol. 16(6), 1597\u20131605 (2009).","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"82654_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1308\/rcsann.2016.0039","volume":"98","author":"NN Basu","year":"2016","unstructured":"Basu, N. N., Littlechild, S., Barr, L., Ross, G. L. & Evans, D. G. Attitudes to contralateral risk reducing mastectomy among breast and plastic surgeons in England. Ann. R. Coll. Surg. Engl. 98(2), 121\u2013127 (2016).","journal-title":"Ann. R. Coll. Surg. Engl."},{"issue":"4","key":"82654_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamasurg.2015.3601","volume":"151","author":"K Yao","year":"2016","unstructured":"Yao, K. et al. Survey of the deficits in surgeons\u2019 knowledge of contralateral prophylactic mastectomy. JAMA Surg. 151(4), 391\u2013393 (2016).","journal-title":"JAMA Surg."},{"key":"82654_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12957-015-0638-y","volume":"13","author":"NN Basu","year":"2015","unstructured":"Basu, N. N., Ross, G. L., Evans, D. G. & Barr, L. The Manchester guidelines for contralateral risk-reducing mastectomy. World J. Surg. Oncol. 13, 237 (2015).","journal-title":"World J. Surg. Oncol."},{"issue":"1","key":"82654_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1245\/s10434-016-5648-7","volume":"24","author":"TM Tuttle","year":"2017","unstructured":"Tuttle, T. M. et al. Guidelines for guidelines: an assessment of the American Society of breast surgeons contralateral prophylactic mastectomy consensus statement. Ann. Surg. Oncol. 24(1), 1\u20132 (2017).","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"82654_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10689-013-9694-z","volume":"13","author":"DG Evans","year":"2014","unstructured":"Evans, D. G. et al. Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. Fam. Cancer 13(2), 189\u2013196 (2014).","journal-title":"Fam. Cancer"},{"issue":"11","key":"82654_CR28","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/jmg.40.11.807","volume":"40","author":"E Amir","year":"2003","unstructured":"Amir, E. et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J. Med. Genet. 40(11), 807\u2013814 (2003).","journal-title":"J. Med. Genet."},{"key":"82654_CR29","doi-asserted-by":"crossref","unstructured":"Evans, D. G., Astley, S., Stavrinos, P., Harkness, E., Donnelly, L. S., Dawe, S., et al. Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study. Programme Grants for Applied Research. Southampton (UK) (2016).","DOI":"10.3310\/pgfar04110"},{"key":"82654_CR30","doi-asserted-by":"publisher","first-page":"f3829","DOI":"10.1136\/bmj.f3829","volume":"346","author":"DG Evans","year":"2013","unstructured":"Evans, D. G., Graham, J., O\u2019Connell, S., Arnold, S. & Fitzsimmons, D. Familial breast cancer: summary of updated NICE guidance. BMJ 346, f3829 (2013).","journal-title":"BMJ"},{"key":"82654_CR31","unstructured":"Ellis IO CP, Hales S, Lee AHS, Pinder SE et al. Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. 1\u201316 (2016)."},{"issue":"8","key":"82654_CR32","doi-asserted-by":"publisher","first-page":"e003179","DOI":"10.1136\/bmjopen-2013-003179","volume":"3","author":"J Neuburger","year":"2013","unstructured":"Neuburger, J., Macneill, F., Jeevan, R., van der Meulen, J. H. & Cromwell, D. A. Trends in the use of bilateral mastectomy in England from 2002 to 2011: retrospective analysis of hospital episode statistics. BMJ Open 3(8), e003179 (2013).","journal-title":"BMJ Open"},{"issue":"4","key":"82654_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ejso.2011.12.014","volume":"38","author":"U Guth","year":"2012","unstructured":"Guth, U. et al. Increasing rates of contralateral prophylactic mastectomy\u2014a trend made in USA?. Eur. J. Surg. Oncol. 38(4), 296\u2013301 (2012).","journal-title":"Eur. J. Surg. Oncol."},{"issue":"10","key":"82654_CR34","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1245\/s10434-015-4745-3","volume":"22","author":"F Wang","year":"2015","unstructured":"Wang, F. et al. Negative genetic testing does not deter contralateral prophylactic mastectomy in younger patients with greater family histories of breast cancer. Ann. Surg. Oncol. 22(10), 3338\u20133345 (2015).","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"82654_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1080\/0284186X.2019.1648860","volume":"59","author":"T Terkelsen","year":"2020","unstructured":"Terkelsen, T., Ronning, H. & Skytte, A. B. Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer. Acta Oncol. 59(1), 60\u201365 (2020).","journal-title":"Acta Oncol."},{"issue":"6","key":"82654_CR36","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1002\/cam4.1519","volume":"7","author":"N Elsayegh","year":"2018","unstructured":"Elsayegh, N. et al. Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer. Cancer Med. 7(6), 2718\u20132726 (2018).","journal-title":"Cancer Med."},{"issue":"9","key":"82654_CR37","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1002\/ijc.23340","volume":"122","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe, K. A. et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int. J. Cancer 122(9), 2017\u20132022 (2008).","journal-title":"Int. J. Cancer"},{"issue":"7","key":"82654_CR38","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1200\/JCO.2007.12.6078","volume":"26","author":"KA Metcalfe","year":"2008","unstructured":"Metcalfe, K. A. et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J. Clin. Oncol. 26(7), 1093\u20131097 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"82654_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejso.2015.03.021","volume":"41","author":"NND-HM Basu","year":"2015","unstructured":"Basu, N.N.D.-H.M. et al. Breast surgeons\u2019 attitudes towards bilateral risk reducing mastectomy\u2014a comparison between the UK, the US, France and Germany. Eur. J. Surg. Oncol. 41(6), 23 (2015).","journal-title":"Eur. J. Surg. Oncol."},{"issue":"7","key":"82654_CR40","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1053\/ejso.2000.0986","volume":"26","author":"F Lalloo","year":"2000","unstructured":"Lalloo, F. et al. A protocol for preventative mastectomy in women with an increased lifetime risk of breast cancer. Eur. J. Surg. Oncol. 26(7), 711\u2013713 (2000).","journal-title":"Eur. J. Surg. Oncol."},{"issue":"7","key":"82654_CR41","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1245\/s10434-014-4334-x","volume":"22","author":"CE Rutter","year":"2015","unstructured":"Rutter, C. E., Park, H. S., Killelea, B. K. & Evans, S. B. Growing use of mastectomy for ductal carcinoma-in situ of the breast among young women in the United States. Ann. Surg. Oncol. 22(7), 2378\u20132386 (2015).","journal-title":"Ann. Surg. Oncol."},{"issue":"10","key":"82654_CR42","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1245\/s10434-017-5931-2","volume":"24","author":"ME Miller","year":"2017","unstructured":"Miller, M. E. et al. Contralateral breast cancer risk in women with ductal carcinoma in situ: is it high enough to justify bilateral mastectomy?. Ann. Surg. Oncol. 24(10), 2889\u20132897 (2017).","journal-title":"Ann. Surg. Oncol."},{"issue":"2","key":"82654_CR43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","volume":"19","author":"ER Copson","year":"2018","unstructured":"Copson, E. R. et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 19(2), 169\u2013180 (2018).","journal-title":"Lancet Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82654-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82654-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82654-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:30:42Z","timestamp":1697761842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-82654-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["82654"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-82654-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"21 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2847"}}